Literature DB >> 25004085

Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice.

Natalie M Frederick1, Julie Bertho2, Kishan K Patel1, Geraldine T Petr3, Ekaterina Bakradze4, Sylvia B Smith5, Paul A Rosenberg6.   

Abstract

Oxidative stress has been implicated in the pathogenesis of Huntington's disease (HD), however, the origin of the oxidative stress is unknown. System xc(-) plays a role in the import of cystine to synthesize the antioxidant glutathione. We found in the STHdh(Q7/Q7) and STHdh(Q111/Q111) striatal cell lines, derived from neuronal precursor cells isolated from knock-in mice containing 7 or 111 CAG repeats in the huntingtin gene, that there is a decrease in system xc(-) function. System xc(-) is composed of two proteins, the substrate specific transporter, xCT, and an anchoring protein, CD98. The decrease in function in system xc(-) that we observed is caused by a decrease in xCT mRNA and protein expression in the STHdh(Q111/Q111) cells. In addition, we found a decrease in protein and mRNA expression in the transgenic R6/2 HD mouse model at 6weeks of age. STHdh(Q111/Q111) cells have lower basal levels of GSH and higher basal levels of ROS. Acute inhibition of system xc(-) causes greater increase in oxidative stress in the STHdh(Q111/Q111) cells than in the STHdh(Q7/Q7) cells. These results suggest that a defect in the regulation of xCT may be involved in the pathogenesis of HD by compromising xCT expression and increasing susceptibility to oxidative stress.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glutamate uptake; Glutathione; Huntington’s disease; Oxidative stress; STHdh cells; xCT

Mesh:

Substances:

Year:  2014        PMID: 25004085      PMCID: PMC4186714          DOI: 10.1016/j.neuint.2014.06.017

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  74 in total

1.  Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation.

Authors:  Hideyo Sato; Shinobu Nomura; Kanako Maebara; Kanako Sato; Michiko Tamba; Shiro Bannai
Journal:  Biochem Biophys Res Commun       Date:  2004-12-03       Impact factor: 3.575

2.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

3.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

Review 4.  Excitotoxic injury of the neostriatum: a model for Huntington's disease.

Authors:  M DiFiglia
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

5.  PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.

Authors:  Taiji Tsunemi; Travis D Ashe; Bradley E Morrison; Kathryn R Soriano; Jonathan Au; Ruben A Vázquez Roque; Eduardo R Lazarowski; Vincent A Damian; Eliezer Masliah; Albert R La Spada
Journal:  Sci Transl Med       Date:  2012-07-11       Impact factor: 17.956

6.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

7.  Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.

Authors:  Jonathan H Fox; David S Barber; Bhupinder Singh; Birgit Zucker; Mary K Swindell; Fran Norflus; Rodica Buzescu; Raman Chopra; Robert J Ferrante; Aleksey Kazantsev; Steven M Hersch
Journal:  J Neurochem       Date:  2004-10       Impact factor: 5.372

8.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

9.  Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.

Authors:  Márcio Ribeiro; Tatiana R Rosenstock; Teresa Cunha-Oliveira; Ildete L Ferreira; Catarina R Oliveira; A Cristina Rego
Journal:  Free Radic Biol Med       Date:  2012-09-14       Impact factor: 7.376

Review 10.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

View more
  13 in total

1.  Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease.

Authors:  Juan I Sbodio; Solomon H Snyder; Bindu D Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-19       Impact factor: 11.205

Review 2.  Gasotransmitter hydrogen sulfide signaling in neuronal health and disease.

Authors:  Bindu D Paul; Solomon H Snyder
Journal:  Biochem Pharmacol       Date:  2017-12-01       Impact factor: 5.858

Review 3.  Cysteine Metabolism in Neuronal Redox Homeostasis.

Authors:  Bindu D Paul; Juan I Sbodio; Solomon H Snyder
Journal:  Trends Pharmacol Sci       Date:  2018-03-09       Impact factor: 14.819

4.  Fibroblast Growth Factor 9 Stimulates Neuronal Length Through NF-kB Signaling in Striatal Cell Huntington's Disease Models.

Authors:  Issa Olakunle Yusuf; Hsiu-Mei Chen; Pei-Hsun Cheng; Chih-Yi Chang; Shaw-Jenq Tsai; Jih-Ing Chuang; Chia-Ching Wu; Bu-Miin Huang; H Sunny Sun; Chuan-Mu Chen; Shang-Hsun Yang
Journal:  Mol Neurobiol       Date:  2021-01-09       Impact factor: 5.590

Review 5.  The importance of the excitatory amino acid transporter 3 (EAAT3).

Authors:  Walden E Bjørn-Yoshimoto; Suzanne M Underhill
Journal:  Neurochem Int       Date:  2016-05-24       Impact factor: 3.921

Review 6.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

Review 7.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

Review 8.  Regulators of the transsulfuration pathway.

Authors:  Juan I Sbodio; Solomon H Snyder; Bindu D Paul
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

Review 9.  Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities.

Authors:  Juan I Sbodio; Solomon H Snyder; Bindu D Paul
Journal:  Antioxid Redox Signal       Date:  2018-05-04       Impact factor: 8.401

Review 10.  Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?

Authors:  Jan Lewerenz; Pamela Maher
Journal:  Front Neurosci       Date:  2015-12-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.